Onconetix

ONCO · NASDAQ

$0.4064−$0.0239 (−5.55%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.4303

About ONCO

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 2 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Employees: 5
Headquarters: Cincinnati, Ohio
Listed: Feb 18, 2022
Sector: Health Care
Industry: Biotechnology
Website: onconetix.com

Leadership

Onconetix executives
Name	Title	Age
Karina Fedasz	—	52
Andrew Oakley	—	63
Thomas Meier	—	63
Timothy Ramdeen	—	33
Simon Tarsh	—	63

Similar companies

Companies in the same industry as Onconetix

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.